Dapsone-induced optic atrophy and motor neuropathy
Blindness is one of the most serious side effects of treatment with drugs. We report a case of a young man who became blind and developed weakness of the legs after inappropriate use of dapsone. This is the first report of optic atrophy in association with dapsone.
Case report
A 20-year-old healthy Sudanese man was convinced that a lipoma on his shoulder was a lepromatous nodule. To cure his "leprosy" he took dapsone 600 mg daily for 10 days. Eleven days later he was admitted to hospital with vomiting, dizziness, and blurred vision. He looked ill and had cyanotic mucous membranes. No other physical abnormalities were noted. Dapsone poisoning was diagnosed, though tests for methaemoglobinaemia were not done. His condition improved when he was treated with fluid replacement and ascorbic acid. Two days later he was completely well and was discharged. He was told not to take dapsone and reassured that he did not have leprosy.
He returned three days later with blurred vision, generalised muscular pains, and difficulty in climbing stairs. He denied taking dapsone or any other drugs since discharge from hospital. Visual acuity was reduced in both eyes to counting fingers only. There was bilateral restriction of peripheral visual fields. Haemorrhages and exudates were present in both fundi, but the optic discs were normal. There were no other cranial nerve lesions. He had severe weakness in both legs and obvious foot drop on the left. Tendon reflexes were symmetrically decreased in the legs, but plantar reflexes were normal. There was no sensory deficit.
Results of laboratory tests on second admission were: haemoglobin concentration 14-8 g/dl, white blood cell count 5-4 x 109/1 (5400/mm3), and erythrocyte sedimentation rate 3 mm in first h. No reticulocytes were seen and the red-cell sickling test gave a negative result. Results of cerebrospinal fluid examination and liver function tests were normal, as were fasting blood sugar concentration and concentrations of plasma urea and electrolytes.
Dapsone-induced motor neuropathy was diagnosed, and this drug was also considered as a cause of his blindness. A month after admission the visual loss persisted and both optic discs became pale, suggesting optic atrophy. Some of the exudates and haemorrhages, however, had cleared. Neither vision nor weakness showed any improvement during six months of follow-up.
Comment
The predominantly motor peripheral neuropathy, absence of sensory features, and clear drug history strongly incriminate dapsone. Case report A 60-year-old man, who had previously been given only phenoxymethylpenicillin, was admitted to hospital with tuberculous meningitis. He was treated with isoniazid, ethambutol, and streptomycin for one week and then with isoniazid, ethambutol, and rifampicin. After two weeks he was given nystatin, flucloxacillin, and gentamicin for one week for intercurrent infections and then dexamethasone 12 mg/day for one week, after which it was gradually withdrawn over about five weeks. Diarrhoea developed one week after nystatin, flucloxacillin, and gentamicin were stopped and soon after the initial dose of dexamethasone had been halved. The diarrhoea resolved after three days but recurred five weeks later, when dexamethasone was withdrawn. Pseudomembranous colitis was diagnosed and histologically confirmed after two weeks. Rifampicin was stopped, dexamethasone was restarted in low dosage, and he was given two one-week courses of vancomycin 2 g by mouth daily separated by one week, during which his diarrhoea returned. Sigmoidoscopic appearances were unchanged after one week but almost normal after two weeks. The diarrhoea settled within three weeks and did not return.
Fresh stools or biopsy specimens were analysed for Cl difficile or its toxin, as described elsewhere.3 Isolates were identified by standard methods.' Minimum inhibitory concentrations of several antibiotics were determined by inoculating 10' colony-forming units on DST (Oxoid CM 261) plus 6 % saponin-lysed horse blood, containing appropriate concentrations of antibiotic. Cl difficile 104/g wet weight of faeces was isolated on the day on which rifampicin was stopped and not thereafter in three samples taken after the first course of vancomycin, in faeces and biopsy material collected during the relapse of diarrhoea, or in two samples of faeces collected during the second course of vanomycin. No toxin was detected in the only stool examined butthe Cl difficile was toxigenic in vitro. The isolate of Cl difficile was resistant to tetracycline (64 mg/l), erythromycin (>64 mg/l), and rifampicin (>100 mg/l), and relatively resistant to penicillin (4 mg/l) and clindamycin (2 mg/l), but was sensitive to metronidazole (0 5 mg/I) and vancomycin (2 mg/l). The patient was treated with prazosin hydrochloride 0 5 mg twice daily increasing gradually to 10 mg twice daily. Before treatment her rectal temperature had been stable around 37°C, but on the third treatment day it started to fall to reach a nadir on the ninth day (figure). Thereafter it remained stable at 35 6'C. Extensive laboratory investigations showed no abnormality. Thyroid function was normal. Prazosin was stopped and her temperature rose again to normal within two days. One week later she was rechallenged with the drug and again her temperature dropped to 35°C. The oral and skin temperatures changed in parallel with the rectal temperature. Prazosin was withdrawn and she was given propranolol and hydralazine, which controlled her hypertension equally well. Her body temperature has been normal ever since.

To our knowledge hypothermia has not been described as a side effect of prazosin. This case, however, shows that it may be. The hypothermia during the first treatment period could have been fortuitous, but the result of the second challenge strongly suggests that the drop in temperature was related to the drug. The hypothermia was unlikely to have been due to the reduction of blood pressure per se, since subsequent treatment with propranolol and hydralazine did not lower temperature but similarly lowered blood pressure.
The mechanism whereby prazosin could cause hypothermia remains unknown. The absence of shivering in our patient and the fact that core temperature fell argue against a purely peripheral cause. Therefore it probably resulted from depression of the hypothalamic thermoregulatory centre. Chlorpromazine, a drug with peripheral and central a-blocking properties, also produces hypothermia,3 and the mechanism by which prazosin lowered body temperature in our patient may be similar. There is some experimental evidence that prazosin may exert a central action.4 A low body temperature in a patient being treated with prazosin should therefore alert the physician to this possible side effect.
